How to evaluate plaque vulnerability in animal models of atherosclerosis?
Prevention of heart attack and stroke depends on detection of vulnerable plaques and development of plaque-stabilizing therapies. In turn, progress in diagnostics and treatment is contingent on our understanding of molecular mechanisms of plaque vulnerability. Animal models are essential for testing mechanistic hypotheses in a controlled manner. Currently, there is no single, golden standard animal model of a vulnerable plaque. However, the whole range of experimental approaches is readily available. It includes traditional models of atherosclerosis combined with new 'vulnerability endpoints', as well as several models featuring spontaneous or induced plaque rupture/thrombosis. This review summarizes current literature on the animal models of vulnerable atherosclerotic plaques.
Rekhter
Mark D
MD
Department of Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, MI 48105, USA. mark.rekhter@pfizer.com
D000818:Animals; D001161:Arteriosclerosis / Q000473:pathology*; D051379:Mice; D023421:Models, Animal; D011817:Rabbits; D051381:Rats; D012107:Research Design; D013927:Thrombosis / Q000473:pathology*